We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?
Read MoreHide Full Article
We expect Biogen Inc. (BIIB - Free Report) to beat expectations when it reports fourth-quarter and full- year 2019 results on Jan 30, before market open.In the last reported quarter, the company delivered a positive earnings surprise of 10.88%.
Biogen’s shares have declined 15.7% in the past year compared with the industry’s decrease of 4.7% in the same time frame.
Biogen’s earnings performance has been strong as it delivered a positive surprise in each of the four trailing quarters with the average being 9.30%.
Let’s see how things have shaped up for this announcement.
Factors to Consider
Biogen’s third-quarter MS revenues, excluding Ocrevus royalties, were almost flat over year and we expect fourth-quarter performance to have been similar. Biogen receives royalties on U.S. sales of Roche’s (RHHBY - Free Report) newly launched MS drug, Ocrevus which is likely to have contributed significantly to the top line. The Zacks Consensus Estimate for Ocrevus royalties is $192 million.
Among the MS drugs, Tecfidera’s U.S. revenues are likely to have been supported by patient growth. Meanwhile, ex U.S. Tecfidera revenues are likely to have benefited from volumes increases in Europe and Japan in the fourth quarter, which might have offset the impact of ongoing price decreases in certain European countries. U.S. sales of another MS drug, Tysabri may have been hurt by Ocrevus launch.
The Zacks Consensus Estimate for sales of Tecfidera in the fourth quarter is pegged at $1.13 billion while that for Tysabri is $466 million.
Meanwhile, combined interferon revenues (Avonex and Plegridy) are likely to have declined due to transition of patients to other oral or high efficacy MS therapies as well as higher discounts and allowance.
Spinraza sales are likely to have been driven by continued patient growth in U.S. markets across both mature and new markets and strong performance in established markets such as EU and Japan in ex-U.S. segment. The Zacks Consensus Estimate for sales of Spinraza is $549 million.
On the third-quarter conference call, Biogen had said that it witnessed some negative impact of Novartis’ new SMA treatment, Zolgensma’s launch on Spinraza’s U.S. sales in this segment. Zolgensma is approved to treat children under two years old, which represents about 5% of the prevalent market. An update is expected on the fourth-quarter conference call.
Interestingly, biosimilars contributed significantly to Biogen’s top line in the first three quarters of 2019 driven mainly by Imraldi’s launch, a trend that most likely continued in the fourth quarter. The Zacks Consensus Estimate for sales of biosimilars is $201 million.
Importantly, in October, Biogen revealed controversial plans to pursue U.S. regulatory approval of aducanumab based on positive results of a new analysis of larger dataset from the discontinued ENGAGE and EMERGE studies, which became available after the studies were ceased.
In March, Biogen and Eisai had discontinued ENGAGE and EMERGE following a futility analysis, which relied on an earlier and smaller dataset. Biogen, in October, had said that a new analysis of the larger dataset showed a different outcome than the one predicted at the time of the futility analysis. In October, Biogen said it plans to submit a biologics license application (BLA) seeking approval of aducanumab to the FDA in early 2020.
Numerous investor questions are expected on Biogen’s timeline for filing the regulatory application for aducanumab on the call.
Earnings Whispers
Our proven model predicts an earnings beat for Biogen in the soon-to-be-reported quarter because it has the right combination of two key ingredients. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise.
Earnings ESP: Biogens Earnings ESP is +3.95% as the Zacks Consensus Estimate of $7.95 is lower than the Most Accurate Estimate of $8.27. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Biogen has a Zacks Rank #3.
Other Stocks to Consider
Here are some other large biotech stocks that also have the right combination of elements to beat on earnings this time around:
Alexion has an Earnings ESP of +5.97% and a Zacks Rank #1. The company is scheduled to release results on Jan 30.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?
We expect Biogen Inc. (BIIB - Free Report) to beat expectations when it reports fourth-quarter and full- year 2019 results on Jan 30, before market open.In the last reported quarter, the company delivered a positive earnings surprise of 10.88%.
Biogen’s shares have declined 15.7% in the past year compared with the industry’s decrease of 4.7% in the same time frame.
Biogen’s earnings performance has been strong as it delivered a positive surprise in each of the four trailing quarters with the average being 9.30%.
Biogen Inc. Price and EPS Surprise
Biogen Inc. price-eps-surprise | Biogen Inc. Quote
Let’s see how things have shaped up for this announcement.
Factors to Consider
Biogen’s third-quarter MS revenues, excluding Ocrevus royalties, were almost flat over year and we expect fourth-quarter performance to have been similar. Biogen receives royalties on U.S. sales of Roche’s (RHHBY - Free Report) newly launched MS drug, Ocrevus which is likely to have contributed significantly to the top line. The Zacks Consensus Estimate for Ocrevus royalties is $192 million.
Among the MS drugs, Tecfidera’s U.S. revenues are likely to have been supported by patient growth. Meanwhile, ex U.S. Tecfidera revenues are likely to have benefited from volumes increases in Europe and Japan in the fourth quarter, which might have offset the impact of ongoing price decreases in certain European countries. U.S. sales of another MS drug, Tysabri may have been hurt by Ocrevus launch.
The Zacks Consensus Estimate for sales of Tecfidera in the fourth quarter is pegged at $1.13 billion while that for Tysabri is $466 million.
Meanwhile, combined interferon revenues (Avonex and Plegridy) are likely to have declined due to transition of patients to other oral or high efficacy MS therapies as well as higher discounts and allowance.
Spinraza sales are likely to have been driven by continued patient growth in U.S. markets across both mature and new markets and strong performance in established markets such as EU and Japan in ex-U.S. segment. The Zacks Consensus Estimate for sales of Spinraza is $549 million.
On the third-quarter conference call, Biogen had said that it witnessed some negative impact of Novartis’ new SMA treatment, Zolgensma’s launch on Spinraza’s U.S. sales in this segment. Zolgensma is approved to treat children under two years old, which represents about 5% of the prevalent market. An update is expected on the fourth-quarter conference call.
Interestingly, biosimilars contributed significantly to Biogen’s top line in the first three quarters of 2019 driven mainly by Imraldi’s launch, a trend that most likely continued in the fourth quarter. The Zacks Consensus Estimate for sales of biosimilars is $201 million.
Importantly, in October, Biogen revealed controversial plans to pursue U.S. regulatory approval of aducanumab based on positive results of a new analysis of larger dataset from the discontinued ENGAGE and EMERGE studies, which became available after the studies were ceased.
In March, Biogen and Eisai had discontinued ENGAGE and EMERGE following a futility analysis, which relied on an earlier and smaller dataset. Biogen, in October, had said that a new analysis of the larger dataset showed a different outcome than the one predicted at the time of the futility analysis. In October, Biogen said it plans to submit a biologics license application (BLA) seeking approval of aducanumab to the FDA in early 2020.
Numerous investor questions are expected on Biogen’s timeline for filing the regulatory application for aducanumab on the call.
Earnings Whispers
Our proven model predicts an earnings beat for Biogen in the soon-to-be-reported quarter because it has the right combination of two key ingredients. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise.
Earnings ESP: Biogens Earnings ESP is +3.95% as the Zacks Consensus Estimate of $7.95 is lower than the Most Accurate Estimate of $8.27. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Biogen has a Zacks Rank #3.
Other Stocks to Consider
Here are some other large biotech stocks that also have the right combination of elements to beat on earnings this time around:
Gilead Sciences (GILD - Free Report) with an Earnings ESP of +4.45% and a Zacks Rank #3. The company is scheduled to release results on Feb 4. You can see the complete list of today’s Zacks #1 Rank stocks here.
Alexion has an Earnings ESP of +5.97% and a Zacks Rank #1. The company is scheduled to release results on Jan 30.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>